PHAT News and Press, Phathom Pharmaceuticals Inc. From 03/26/24

A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointesti...

2024-03-18 01:19:05 ET Summary The FDA has set a target action date of July 19, 2024, for expanded approval of Voquenza, which would target the larger Non-Erosive GERD patient population. The global market for GERD therapies is expected to be $3.4 billion by 2032. A soon-to-be...

2024-03-14 21:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-07 14:11:15 ET Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Conference Call March 7, 2024 08:30 ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Co...

2024-03-07 08:04:36 ET More on Phathom Pharmaceuticals Phathom Pharma Is A Buy Before July PDUFA Phathom Pharmaceuticals expands existing loan and security deal with Hercules Capital Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals Historical ea...

Launched VOQUEZNA® (vonoprazan) tablets in November 2023 for the treatment of Erosive GERD (gastroesophageal reflux disease), achieving net revenues of $0.7 million for the fourth quarter Early physician prescribing demonstrates strong demand for VOQUEZNA Secured expa...

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

Management to host conference call on Thursday, March 7, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestina...

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

2024-02-16 16:37:46 ET Gainers: Iovance Biotherapeutics ( IOVA ) +4% . Microvision ( MVIS ) +3% . Iridium Communications  ( IRDM ) +3% . Playtika Holding  ( PLTK ) +2% . JetBlue Airways  ( JBLU ) +2% . Losers...